The Global Ophthalmic Viscosurgical Devices market was valued at $705.21 million in 2024 and is projected to grow to $1.65 billion by 2034 , with a CAGR of 8.9% during the forecast period, 2024-2034.

Previous research has shown that voretigene neparvovec administered subretinally early in childhood for RPE65-mediated ...

Changing to dailies is worth considering: One study found that people who wear reusable contact lenses are about four times ...

The condition appears to be triggered when the optic nerve swells, choking off its blood supply because the nerve's pathway ...

Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports fourth-quarter ...

On behalf of the Board of Directors, management, and employees of Outlook Therapeutics, I want to extend my deepest gratitude ...

The following is a summary of “Evaluation of macular retinal oximetry across different levels of diabetic retinopathy: a cross sectional study,” published in the January 2025 issue of Ophthalmology by ...

The Hashmanis Group of Hospitals hosted the prestigious Pioneering Innovations in Ophthalmology Conference 2025, bringing together leading international and local experts to discuss groundbreaking ...

Lower rates of both progression of macular fibrosis and intravitreal aflibercept injections were found in those who used the ...

SBL03 was formulated as an ophthalmic gel for non-invasive topical delivery. Its unique ability to infiltrate eye tissues effectively and protect ret ...

Stargardt disease, the most common form of juvenile macular degeneration, results from biallelic mutations in the ABCA4 gene. In a recently published study, researchers at the Institute of Molecular ...

In this Healio Video Perspective from Retina 2025, Ramiro Ribeiro, MD, PhD, of EyePoint Pharmaceuticals, discusses Duravyu, a vorolanib intravitreal insert. According to Ribeiro, in the DAVIO 2 trial, ...